Evidence map›Paper›PMID 31644622›Full record

ArticleAnais brasileiros de dermatologia2019

BRAFV600E and KIT immunoexpression in early-stage melanoma.

Andressa Germano, Leonardo Cardili, Fernando Cintra Lopes Carapeto, Gilles Landman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anais brasileiros de dermatologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andressa GermanoGraduate Studies Program in Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0003-2033-0616
Leonardo CardiliDepartment of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0001-9673-4030
Fernando Cintra Lopes CarapetoGraduate Studies Program in Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0003-2943-8244
Gilles LandmanDepartment of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0001-7441-3068
Universidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.

Indexed as

AdultAgedAged, 80 and overDisease ProgressionFemaleHumansImmunohistochemistryMaleMelanomaMiddle AgedMitogen-Activated Protein KinasesMutationNeoplasm StagingProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitRetrospective StudiesBRAF protein, humanMitogen-Activated Protein KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kit

Identifiers

PMID31644622
PMCPMC7007021
OpenAlexW2980924472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.